We would like to ensure that you are still receiving content that you find useful – please confirm that you would like to continue to receive ILO newsletters.
19 February 2020
In January 2020 the Patented Medicine Prices Review Board released the Meds Entry Watch 2018, which analyses information about medicines approved by the US Food and Drug Administration, the European Medicines Agency or Health Canada in 2017 and 2018.
Consistent with the Canadian Institute for Health Information's December 2019 report (for further details please see "Canadian Institute for Health Information publishes drug spending statistics"), one of the key findings of the Meds Entry Watch 2018 is the continued upward trend in the entry of high-cost products (eg, orphan drugs and oncology products), with nearly two-thirds of the medicines approved internationally in 2017 having treatment costs of more than C$10,000 per year, or C$5,000 per 28-day cycle for oncology medicines.
For further information on this topic please contact Katie Lee at Smart & Biggar by telephone (+1 416 593 5514) or email (firstname.lastname@example.org). The Smart & Biggar website can be accessed at www.smart-biggar.ca.
The materials contained on this website are for general information purposes only and are subject to the disclaimer.
ILO is a premium online legal update service for major companies and law firms worldwide. In-house corporate counsel and other users of legal services, as well as law firm partners, qualify for a free subscription.